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Esophageal adenocarcinoma is an aggres-
sive malignancy with a poor prognosis.
In Western countries, the incidence of
esophageal adenocarcinoma has increased
dramatically in the last three decades.
To improve patient survival and reduce
disease burden, early-stage detection, or
better yet, preventing the progression
of esophageal adenocarcinoma from its
premalignant lesions, constitute the best
short-term options. Barrett’s esophagus is
histologically characterized by the replace-
ment of the normal stratified squa-
mous epithelium of the esophagus with
a columnar epithelium with intestinal
differentiation (Matsuzaki et al., 2010,
2011). Barrett’s esophagus is considered
to be a complication of gastroesophageal
reflux disease and a precursor lesion of
esophageal adenocarcinoma. It is generally
believed that the progression of Barrett’s
esophagus involves a series of histological
changes: non-dysplastic Barrett’s metapla-
sia, low-grade dysplasia, high-grade dys-
plasia, and ultimately, adenocarcinoma.
Although these features justify endoscopic
surveillance for the premalignant stages,
patients with Barrett’s esophagus show
an absolute annual risk of only 0.12%
for the development of esophageal ade-
nocarcinoma (Hvid-Jensen et al., 2011).
Therefore, recommending the invasive
and expensive conventional endoscopic
screening procedure is deemed controver-
sial. In fact, Corley et al. reported that,
within a large community-based popula-
tion, endoscopic surveillance of Barrett’s
esophagus was not associated with a sub-
stantial decrease in the risk of death
from esophageal adenocarcinoma (Corley
et al., 2013). Thus, identification of better
risk stratification biomarkers to determine
the risk of progression from Barrett’s
esophagus to esophageal adenocarcinoma
may improve disease outcome and make
patient management more cost-efficient.
MicroRNAs (miRNAs) are a class of
small non-coding endogenous RNAs,
18–25 nucleotides in length, and are capa-
ble of simultaneous regulation of genes
by binding to target mRNAs, resulting
in mRNA degradation or translational
inhibition. miRNAs participate in many
essential biological processes, including
proliferation, differentiation, apoptosis,
necrosis, autophagy, and stress responses
(Saito et al., 2011b, 2012a). miRNAs have
also been shown to play a potential role in
cancer pathogenesis through their func-
tions as oncogenes or tumor suppressors,
depending on their gene targets (Saito
et al., 2009a, 2011a; Nishizawa and Suzuki,
2013). Compared to mRNAs, miRNAs are
less numerous in humans and have been
proposed to act as better biomarkers by
virtue of their small size, greater stabil-
ity, and capability of regulating hundreds
of mRNAs. Therefore, miRNAs profiling
could improve the risk stratification for
the progression of Barrett’s esophagus to
esophageal adenocarcinoma.
MiRNAs can be profiled on a genome-
wide scale using array or sequencing tech-
nologies. However, very few studies have
been conducted to identify miRNAs as
prognostic biomarkers for the progres-
sion of Barrett’s esophagus to adenocar-
cinoma. Although several cross-sectional
studies using comprehensive array analy-
sis have been reported (Feber et al., 2008;
Kan et al., 2009; Yang et al., 2009; Fassan
et al., 2011; Leidner et al., 2012; Wu et al.,
2013), their results have proved contro-
versial. They compared the expression of
miRNAs across different types of histolog-
ical specimens such as Barrett’s esophagus,
low-grade dysplasia, high-grade dyspla-
sia, and esophageal adenocarcinoma, and
reported that a substantial number of
miRNAs show differential expression in
esophageal tissues (Sakai et al., 2013).
Indeed, they might be useful in revealing
certain mechanisms underlying carcino-
genesis. But, they might be difficult to
identify risk stratification biomarkers. We
should think about much better research
strategies.
Recently, two nice studies were reported
to identify risk stratification biomarkers
for Barrett’s esophagus: one prospective
study and one cross-sectional study. First,
Revilla-Nuin et al. have reported a set of
miRNAs associated with this progression
and provided further validation in two
groups of patients with Barrett’s esoph-
agus, who either developed or did not
develop adenocarcinoma, over a course of
5 years (Revilla-Nuin et al., 2013). Among
24 patients with Barrett’s esophagus, 7
patients progressed to adenocarcinoma
while the other 17 did not. Four miRNAs
(miR-192, miR-194, miR-196a, and miR-
196b) were found to show significantly
higher expression in patients with pro-
gression to esophageal adenocarcinoma
than in patients who did not show disease
progression. Second, Saad et al. conducted
a notable comprehensive microarray pro-
filing for identifying the specific miRNA
signature associated with esophageal ade-
nocarcinoma (Saad et al., 2013). They
analyzed 13 samples from isolated Barrett’s
esophagus, 10 from Barrett’s esopha-
gus adjacent to high-grade dysplasia, 17
from high-grade dysplasia, and 34 from
esophageal adenocarcinoma tissue. They
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identified that miR-21, miR-31, miR-192,
and miR-194 were upregulated in Barrett’s
esophagus adjacent to high-grade dys-
plasia lesions as compared to isolated
Barrett’ esophagus. In addition, these
4 miRNAs were upregulated in a pro-
gressive manner through the Barrett’s
metaplasia-dysplasia-adenocarcinoma
sequence. More importantly, this study
provided findings for Barrett’s esophagus
for two groups: isolated Barrett’s esoph-
agus vs. Barrett’s esophagus adjacent to
high-grade dysplasia. The limitations of
both two papers include the very small
sample size. Larger prospective multi-
institutional studies are warranted to
confirm this result. Another criticism
against the studies using comprehensive
microarray analysis is that these could
not provide the insights how miRNAs
may exert their effects (Saito et al., 2009b,
2012b, 2013).
Since clinical predictors of increased
risk of esophageal adenocarcinoma,
namely, the length of Barrett’s esoph-
agus, male gender, older age, current
tobacco smoking, alcohol consumption,
central obesity, and bile reflux, have been
established, the association between the
expression levels of miRNA in Barrett’s
esophagus and these clinical risk factors
would require further investigation. We
had recently reported that expression lev-
els of miR-221 and miR-222 increased
when cultured esophageal epithelial cells
were exposed to bile acids. miR-221
and miR-222 are known to specifically
target p27Kip1, which in turn inhibits
the proteasomal protein degradation
of CDX2 (caudal-related homolog 2)
(Matsuzaki et al., 2013). Furthermore,
miR-221 and miR-222 expressions are
higher in esophageal adenocarcinoma
than in the surrounding Barrett’s esopha-
gus. We also confirmed that the levels of
p27Kip1 and CDX2 were lower in areas
of esophageal adenocarcinoma than in
those of Barrett’s esophagus. Thus, we
showed that the degradation of CDX2
was enhanced by upregulation of miR-221
and miR-222 on exposure to bile acids.
Although bile acids are known to induce
DNA damage, resistance to apoptosis
through NF-κB activation, and resistance
to autophagy (Fang et al., 2013), the asso-
ciation between bile acids and miRNA
expression has never been reported except
for our results (Masaoka and Suzuki,
2014). In this way, clinical epidemiologi-
cal information would be important and
useful to reveal novel insights of miRNA
in the progression of Barrett’s esophagus
to adenocarcinoma.
In conclusion, on the basis of clin-
ical importance, better risk stratifica-
tion biomarkers to determine the risk of
progression from Barrett’s esophagus to
esophageal adenocarcinoma are expected.
We should deepen our knowledge of
miRNA using clinical materials, hope-
fully with more prospective approach. The
fusion of basic science and clinical sci-
ence research would also be required for
identifying the upstream regulation and
the downstream targets of miRNAs and
understanding their mode of action. These
will facilitate the development of miRNA-
based prevention or therapeutic strategies
for esophageal adenocarcinoma.
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